Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Total Liabilities (2021 - 2025)

Bioregenx (BRGX) has 5 years of Total Liabilities data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 26.69% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $4.8 million, up 26.69%, while the annual FY2024 figure was $3.9 million, 32.36% up from the prior year.
  • Total Liabilities reached $4.8 million in Q3 2025 per BRGX's latest filing, roughly flat from $4.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $4.8 million in Q3 2025 and bottomed at $101553.0 in Q1 2022.
  • Average Total Liabilities over 5 years is $2.1 million, with a median of $1.6 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: increased 10.9% in 2023, then skyrocketed 1480.07% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $211996.0 in 2021, then grew by 22.97% to $260691.0 in 2022, then skyrocketed by 1026.69% to $2.9 million in 2023, then skyrocketed by 32.36% to $3.9 million in 2024, then grew by 23.85% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $4.8 million in Q3 2025, $4.8 million in Q2 2025, and $4.0 million in Q1 2025.